1. Aspergillus, Penicillium and Talaromyces isolated from house dust samples collected around the world. Stud Mycol. 2014;78:63–139.
2. Cytodiagnosis of sinonasal aspergillosis—a case report with brief review of literature. World J Pathol. 2015;4:39–43.
3. Treatment of Aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–360.
4. Evaluation of pulmonary fungal diseases in patients with fungal rhino-sinusitis. Egypt J Chest Dis Tubercul. 2013;62(3):493–500.
5. Invasive maxillary sinus aspergillosis: a case report successfully treated with voriconazole and surgical debridement. Clin Exp Dent. 2014;64:448–451.
6. Invasive maxillary aspergillosis masquerading as malignancy in two cases: utility of cytology as a rapid diagnostic tool. Cytol. 2012;29(3):194–196.
7. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;20(121):156–174.
8. Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. J Med Microbiol. 2010;59(7):834–838.
9. Long-term treatment of invasive sinus, tracheobroncheal, pulmonary and intracerebral aspergillosis in acute lymphoblastic leukaemia. Infection. 2012;40(1):81–85.
10. Aspergillus osteomyelitis of the proximal humerus: a case report. Skeletal Radiol. 2012;41(8):1021–1025.
11. Invasive Aspergillus infection localized to the gastric wall: report of a case. Surg Today. 2013;43(6):682–684.
12. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood. 2012;119(8):1831–1837.
13. Airway and parenchymal manifestations of pulmonary aspergillosis. Respir Med. 2013;107(8):1113–1123.
14. Allergic bronchopulmonary Aspergillosis—a clinical review. J Assoc Physicians India. 2012;60:46–51.
15. Allergic bronchopulmonary aspergillosis. Proc American Thorac Soc. 2010;73:237–244.
16. Invasive pulmonary aspergillosis in an immunocompetent host. Crit Care Shock. 2015;18:43–45.
17. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850–873.
18. Pulmonary Aspergillosis: a clinical update. QJM An Int J Med. 2007;100:317–324.
19. Role of inhaled corticosteroids in the management of serological allergic bronchopulmonary aspergillosis ABPA. Intern Med. 2011;50:855–860.
20. Invasive aspergillosis in developing countries. Med Mycol. 2011;49(Suppl. 1):35–47.
21. Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview. Crit Rev Microbiol. 2013;40(1):30–48.
22. Broncho-pulmonary aspergillosis. Thorax. 1952;7:317–333.
23. Innate immunity and the role of epithelial barrier during Aspergillus fumigatus infection. Current Immunol Rev. 2012;8:254–261.
24. Semi-invasive pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology. 1981;140(2):313–321.
25. Chronic necrotizing pulmonary aspergillosis. Vojnosanit Pregle. 2011;68(11):988–991.
26. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis. 2010;14:479–482.
27. Chronic Aspergillus infections of the respiratory tract: diagnosis, management and antifungal resistance. Curr Opin Infect Dis. 2010;23:584–589.
28. Underlying conditions in chronic pulmonary aspergillosis, including simple aspergilloma. Eur Respir J. 2010;37:865–872.
29. Pulmonary Aspergillosis. Semin Respir Crit Care Med. 2008;282:103–110.
30. Laboratory diagnosis of invasive Aspergillosis: from diagnosis to prediction of outcome. Scientifica. 2013;1:1–29.
31. European conference on infections in leukemia ecil laboratory working groups: Ecil recommendations for the use of biological markers for the diagnosis of invasive fungal diseases. Bone Marrow Transplant. 2012;47:846–854.
32. Fungal infection in cancer patients an international autopsy survey. Eur J Clin Microbiol. 1992;11:09–99.
33. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67(11): .
34. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345–351.
35. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infec. 2010;16:870–877.
36. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infec. 2012;18:403–408.
37. The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay. BioMed Res Int. 2015;43691:1–5.
38. Prevalence and fungal profile of pulmonary aspergillosis in immunocompromised and immunocompetent patients of a tertiary care hospital. Int J Med Res Health Sci. 2013;31:92–97.
39. Identification key for Aspergillus species isolated from maize and soil of Nandi County, Kenya. Adv Microbiol. 2015;5:205–229.
40. Identification of fungi of the genus Aspergillus section Nigri using polyphasic taxonomy. Braz J Microbiol. 2011;42:761–773.
41. Dentification of some Aspergillus species isolated from Dal Lake, Kashmir by traditional approach of morphological observation and culture. Afr J Microbiol Res. 2012;6(29):5824–5827.
42. Microscopic evaluation, molecular identification, antifungal susceptibility, and clinical outcomes in Fusarium, Aspergillus and dematiaceous keratitis. BioMed Res Int. 2013: 1–10.
43. SNaPAfu: a novel single nucleotide polymorphism multiplex assay for Aspergillus fumigatus direct detection, identification and genotyping in clinical specimens. Plos One. 2013;8(10):1–9.
44. Evaluation of MycAssayTM Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. Plos One. 2013;8(4):1–7.
45. Usefulness of molecular biology performed with formaldehyde-fixed paraffin embedded tissue for the diagnosis of combined pulmonary invasive mucormycosis and aspergillosis in an immunocompromised patient. Diagn Pathol. 2010;5:1–7.
46. Molecular characterization of Aspergillus infections in an Iranian educational hospital using RAPD-PCR method. Iran J Basic Med Sci. 2014;17(9):646–650.
47. Pulmonary aspergillosis: clinical presentation, diagnostic tests management and complications. Curr Opin Pulm Med. 2010;16(3):242–250.
48. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay ELISA, and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol. 2013;51:1510–1516.
49. Diagnosis of invasive aspergillosis: recent developments and ongoing challenges. Eur J Clin Invest. 2015;45:647–662.
50. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–770.
51. 1-3-β-d-Glucan assay: a review of its laboratory and clinical application. Lab Med. 2011;42(11):679–685.
52. Allergic aspergillosis of the respiratory tract. Eur Respir Rev. 2014;23:8–29.
53. The volatome of Aspergillus fumigatus. Eukaryot cell. 2014;13(8):1014–1025.
54. Detection of 2-pentylfuran in the breath of patients with Aspergillus fumigatus. Med Mycol. 2009;47:468–476.
55. Advances and challenges in management of invasive mycoses. Lancet. 2005;366:1013–1025.
56. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med. 2006;119(6): .
57. Voriconazole or Amphotericin b as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis. PLoS ONE. 2014;92:e90176.
58. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415.
59. Therapeutic drug monitoring TDM of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162–1176.
60. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing AmBiLoad trial. Clin Infect Dis. 2007;44:1289–1297.
61. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs. 2011;7118:2405–2419.
62. Fungal infection: diagnosis and management. 4th Edition Chichester: Wiley-Blackwell; 2012.
63. Current and future therapies for invasive aspergillosis. Pulm Pharmacol Ther. 2015;32:155–165.
64. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study 1982-1987. Mycoses. 1988;31:476–485.
65. Treatment of pulmonary aspergilloma with itraconazole. Thorax. 1991;46:839–841.
66. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc. 1996;71(1):25–30.
67. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010;51(12):1383–1391.
68. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342:756–762.
69. Prolonged therapeutic response to voriconazole in a case of allergic bronchopulmonary aspergillosis. Arch Bronconeumol. 2007;431:49–51.
70. Case report: allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully treated with voriconazole. J Asthma. 2007;44:891–895.
71. Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole. Mycoses. 1996;39(9–10):371–374.
72. Voriconazole used for treatment of tracheobronchial aspergillosis: a report of two cases. J Clin Trials. 2012;2:117.
73. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686–693.
74. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608615.
75. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J. 2009;102:29.
76. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma. 2012;49:423–433.
77. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122–1131.
78. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother. 2006;50:1878–1880.
79. Voriconazole for chronic pulmonary aspergillosis:a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 2012;31:3231–3239.
80. Intravenous itraconazole. Ann Pharmacother. 2001;35:720–729.
81. Treatment of allergic bronchopulmonary aspergillosis with fluconazole and itraconazole. Med J Armed Force India. 2004;60:128–130.
82. Intravenous itraconazole followed by oral itraconazole for the treatment of Amphotericin B refractory invasive pulmonary aspergillosis. Acta Haematol. 2003;109(3):111118.
83. Kohno S, Izumikawa K. Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus infection. CID 2010:51.
84. Antifungal therapy for invasive aspergillosis. US Pharm. 2013;384:2–5.
85. Azole resistant Aspergillus fumigatus: an emerging problem. Médecine et maladies infectieuses. 2013;43:139–145.
86. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12:141–147.
87. Azole antifungal resistance today: focus on Aspergillus. Curr Infect Dis Rep. 2011;6:485–491.
88. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother. 2012;56:869–874.
89. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67:362–366.
90. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother. 2013;57:2815–2820.
91. Lavergne RA, Morio F, Favennec L, Dominique S, Meis JF, Gargala G, et al. First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France. Antimicrob Agents Chemother59(7):4331–5.
92. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015;70:1522–1526.
93. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domestic homes. Clin Infect Dis. 2013;57:513–520.
94. Voriconazole resistance in Aspergillus fumigatus: should we be concerned? Clin Infect Dis. 2013;574:521–523.
95. Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front Microbiol. 2015;6:428.
96. Nationwide surveillance of azole resistance in Aspergillus disease. Antimicrob Agents Chemother. 2015;59(8):4569–4576.
97. Prospective evaluation of azole resistance in Aspergillus fumigatus clinical isolates in France. Med Mycol. 2015;53(6):593–596.
98. cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother. 2013;57(8):3513–3517.